Key result
Joint and soft-tissue corticosteroid injections in patients taking DOACs resulted in no adverse events of significant bleeding (0%) compared to patients not taking DOACs.
Why the study?
The risk for complications associated with joint and soft-tissue injections in patients taking direct oral anticoagulants was not fully understood.
Do direct oral anticoagulants (DOACs) increase bleeding complications in rehabilitation inpatients receiving joint and soft-tissue corticosteroid injections?
Cohort (n=445)
No
Do direct oral anticoagulants (DOACs) increase bleeding complications in rehabilitation inpatients receiving joint and soft-tissue corticosteroid injections?
Absolute Event Rate: 0% vs 0%
Joint and soft-tissue corticosteroid injections appear safe in rehabilitation inpatients taking DOACs, with no significant bleeding events observed.
May support safety of corticosteroid injections in DOAC users; leaves open need for randomized confirmation in rehabilitation inpatients.
The risk for complications associated with joint and soft-tissue injections in patients taking direct oral anticoagulants (DOACs) is not fully understood. In this retrospective evaluation of 445 inpatients in a rehabilitation hospital who received corticosteroid injections, complications were compared in patients on DOACs with those who were not. After a review of all injections, no adverse events of significant bleeding (intra-articular or extra-articular) were observed. These findings suggest no substantial increase in adverse events associated with the use of DOACs when performing joint and soft-tissue injection procedures in inpatient rehabilitation setting.
No takes yet. Share an insight, caveat, or question.
Nord et al. (2018) conducted a cohort in Inpatients receiving joint and soft-tissue corticosteroid injections (n=445). Direct oral anticoagulants (DOACs) vs. Patients not taking DOACs was evaluated on Adverse events of significant bleeding (intra-articular or extra-articular). Joint and soft-tissue corticosteroid injections in patients taking DOACs resulted in no adverse events of significant bleeding (0%) compared to patients not taking DOACs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: